Pediatric trials for ARV experienced children Coleen K. Cunningham

2/7/01


Click here to start


Table of Contents

Pediatric trials for ARV experienced children Coleen K. Cunningham

Pediatric HIV

Pediatric HIV

Pediatric HIV trends

Reported Rate (%) of Protease Inhibitor Use* among Subjects in PACTG 219 prior to Jan 1, 1996

Pediatric HIV

Mortality Rates (% per year) among HIV infected subjects enrolled in PACTG 219 prior to Jan 1, 1996

Mortality Rates (% per year) by Race/ Ethnicity: HIV infected subjects enrolled in PACTG 219 prior to Jan 1, 1996

Mortality Rates (% per year) by age among HIV infected subjects enrolled in PACTG 219 prior to Jan 1, 1996

Pediatric HIV

Vertical transmission of HIV in PACTG studies: 1993-2000

Pediatric HIV

How do pediatric numbers impact on trial design?

Children cared for at PACTG sites

Racial/ethnic make up PACTG:NICHD

How do pediatric numbers impact on trial design?

Treatment factors unique to pediatrics

Treatment factors unique to pediatrics

Pediatric treatment trials

Trial design options